Pathway
Women's Health
The Approach
How We Approach This Pathway
Why This Approach Fits
Metabolic health, strength, recovery, sleep and sexual wellbeing, considered against symptoms, life stage and personal priorities. Hormones, contraception and pregnancy plans change which options are appropriate, so we start there.
How Care Works
Care is organized around your life stage and what you want from it, with no presumption of motherhood or cosmetic goals. Your treating clinician coordinates with your gynecologist or primary care clinician when you authorize it.
Read Before You Decide
What Is Measured, and What We Ask First
What Is Measured
Laboratory results, symptoms, treatment tolerance and relevant biometric trends are reviewed together by your clinician, on a schedule you agree on at the start.
Before We Show Any Options
We screen for pregnancy, lactation, contraception and fertility plans before any treatment is considered. Some medicines are not appropriate in those situations, and we do not show them until we know.
By Life Stage
Where Care Starts
Reproductive Years
Cycle changes, weight, energy, sleep and desire are reviewed together with thyroid, iron and medication causes. Pregnancy plans and contraception shape every option we discuss.
PCOS and Metabolic Health
Weight, glucose and lipid review alongside your gynecologist or endocrinologist. GLP-1 medicines may be discussed, and we are plain about how modest and uncertain the evidence is.
Postpartum and Beyond
We do not rush to prescribe after delivery or while breastfeeding. Strength, sleep, nutrition and recovery come first, and any medicine waits for clinician review of lactation.
Perimenopause and Menopause
Sleep, body composition, strength and bone health are the practical focus. Hormone therapy is one option, decided with you and your gynecologist. See the Menopause and Midlife pathway for how we approach it.
Care Plans We May Discuss
Options for This Pathway
Hormone Review
Hormone Review
Intimacy and Vitality
Learn More →Metabolic Support
Metabolic Support
Weight and Metabolic Health
Learn More →Longevity Panel
Longevity Panel
Energy and Longevity
Learn More →This page describes a care pathway and is not a treatment recommendation. Compounded medications are not FDA-approved or evaluated for safety, effectiveness or quality. Prescriptions are issued only after clinician review.
The Evidence
What the Research Says
Almaradweh and Mousa, Cureus, 2026 (narrative review for obstetrician-gynecologists)
Reviewed GLP-1 and GIP/GLP-1 medicines across the reproductive spectrum, including pharmacokinetic interactions with oral hormonal contraceptives, preconception washout, inadvertent early-pregnancy exposure, postpartum use and breastfeeding. It concluded that pregnancy and lactation data remain limited and that counseling should be individualized and centered on pregnancy intention and contraceptive reliability.
Read the Source ↗Yu et al., Obstetrics & Gynecology, 2026 (retrospective cohort)
People who were taking semaglutide when they became pregnant (429) had higher risks of excessive gestational weight gain, gestational diabetes, excessive fetal growth and cesarean delivery than nonusers (2,203). Former users were also elevated, which suggests rebound weight and metabolic effects after stopping. It is observational and cannot prove cause.
Read the Source ↗Uysal et al., Scientific Reports, 2026 (systematic review and meta-analysis)
Seven cohort studies with over 40,000 exposed pregnancies found no statistically significant increase in major congenital malformations, stillbirth, miscarriage, small-for-gestational-age or preterm birth. The authors call the evidence cautiously reassuring but low in certainty, and this is not a reason to continue a medicine through pregnancy.
Read the Source ↗Forslund et al., European Journal of Endocrinology, 2026 (systematic review of 11 randomized trials)
In women with PCOS and overweight or obesity, GLP-1 medicines added to usual care lowered BMI by about 1.4 kg/m2 (low certainty). Evidence for glucose, hirsutism, menstrual regularity, quality of life or cost-effectiveness was insufficient or absent.
Read the Source ↗Simon et al., Journal of Women's Health, 2022 (RECONNECT phase 3 subgroup analyses)
Across 1,202 premenopausal women with hypoactive sexual desire disorder, bremelanotide 1.75 mg as needed improved desire and reduced distress versus placebo in prespecified age, weight and BMI subgroups. It is FDA-approved only for this use.
Read the Source ↗Zhao et al., Journal of Orthopaedic Surgery and Research, 2025 (17 randomized trials, 690 women)
Resistance training significantly improved bone mineral density at the lumbar spine, femoral neck and total hip in postmenopausal women.
Read the Source ↗Common Questions
Do You Ask About Pregnancy and Breastfeeding First?+
Yes. We ask whether you are pregnant, breastfeeding or planning a pregnancy before any option is shown. Some medicines are not appropriate in those situations, and we will not present them until we know.
Can a GLP-1 Medicine Affect My Birth Control?+
It can. Tirzepatide labeling advises that oral hormonal contraceptives may be less effective, particularly after the first dose and after each dose increase, and recommends a non-oral or barrier method for four weeks after starting and after each escalation. Your clinician reviews your method before prescribing and tells you what to do.
What If I Want to Become Pregnant?+
Tell us at the start. The semaglutide manufacturer advises stopping at least two months before a planned pregnancy, and recent observational data show higher gestational weight gain, gestational diabetes and cesarean delivery after use around conception. We plan the timing with you and your obstetric clinician.
Do You Treat PCOS?+
We can help with the weight and metabolic side alongside your gynecologist or endocrinologist. A 2026 review of 11 randomized trials found GLP-1 medicines modestly lowered BMI in women with PCOS and overweight, while evidence for menstrual regularity, hirsutism and glucose was insufficient. We tell you that rather than promise more.
Do You Prescribe Hormone Therapy for Menopause?+
Hormone therapy is one option, and whether it is right depends on your age, time since menopause, history and symptoms. Our Menopause and Midlife pathway explains how we review that, and we coordinate with your gynecologist when you authorize it.
Is PT-141 Appropriate for Me?+
Bremelanotide is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Low desire has many causes, so we look at thyroid, iron, sleep, mood and medications first. It is not offered if you are pregnant or breastfeeding.
Can GLP-1 Medicines Cause Hair Loss?+
Reports exist, most often with semaglutide and tirzepatide. They come mainly from database analyses, a plausible cause is shedding after rapid weight loss, and causality has not been established. Adequate protein, iron and a gradual pace are part of how we monitor.
Will I Be Treated by a Women's Health Specialist?+
Care is led by SOVRYN's treating clinicians, who decide every prescription. We coordinate with your own gynecologist or primary care clinician when you authorize it, and we refer you to one when a question is outside what telehealth should handle.
Start Your Assessment
Ten minutes, no card, reviewed by a clinician.